[ad_1]
Cassetta, L. & Pollard, J. W. Focusing on macrophages: therapeutic approaches in most cancers. Nat. Rev. Drug Discov. 17, 887–904 (2018).
Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to remedy. Immunity 41, 49–61 (2014).
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Tumour-associated macrophages as remedy targets in oncology. Nat. Rev. Clin. Oncol. 14, 399–416 (2017).
Poh, A. R. & Ernst, M. Focusing on macrophages in most cancers: from bench to bedside. Entrance. Oncol. 8, 49 (2018).
Cotechini, T., Medler, T. R. & Coussens, L. M. Myeloid cells as targets for remedy in stable tumors. Most cancers J. 21, 343–350 (2015).
Gentles, A. J. et al. The prognostic panorama of genes and infiltrating immune cells throughout human cancers. Nat. Med. 21, 938–945 (2015).
Takeya, M. & Komohara, Y. Position of tumor-associated macrophages in human malignancies: pal or foe? Pathol. Int. 66, 491–505 (2016).
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G. & Galluzzi, L. Macrophages and metabolism within the tumor microenvironment. Cell Metab. 30, 36–50 (2019).
DeNardo, D. G. & Ruffell, B. Macrophages as regulators of tumour immunity and immunotherapy. Nat. Rev. Immunol. 19, 369–382 (2019).
Singhal, S. et al. Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung most cancers. Sci. Transl. Med. 11, eaat1500 (2019).
Fehres, C. M., Unger, W. W. J., Garcia-Vallejo, J. J. & van Kooyk, Y. Understanding the biology of antigen cross-presentation for the design of vaccines in opposition to most cancers. Entrance. Immunol. 5, 149 (2014).
Kurts, C., Robinson, B. W. S. & Knolle, P. A. Cross-priming in well being and illness. Nat. Rev. Immunol. 10, 403–414 (2010).
Joffre, O. P., Segura, E., Savina, A. & Amigorena, S. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 12, 557–569 (2012).
Cruz-Leal, Y. et al. The vacuolar pathway in macrophages performs a significant function in antigen cross-presentation induced by the pore-forming protein sticholysin II encapsulated into liposomes. Entrance. Immunol. 9, 2473 (2018).
Embgenbroich, M. & Burgdorf, S. Present ideas of antigen cross-presentation. Entrance. Immunol. 9, 1643 (2018).
Shen, L., Sigal, L. J., Boes, M. & Rock, Ok. L. Essential function of cathepsin S in producing peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity 21, 155–165 (2004).
Surana, S., Bhat, J. M., Koushika, S. P. & Krishnan, Y. An autonomous DNA nanomachine maps spatiotemporal pH adjustments in a multicellular dwelling organism. Nat. Commun. 2, 340 (2011).
Chakraborty, Ok., Leung, Ok. & Krishnan, Y. Excessive lumenal chloride within the lysosome is essential for lysosome operate. Elife 6, e28862 (2017).
Narayanaswamy, N. et al. A pH-correctable, DNA-based fluorescent reporter for organellar calcium. Nat. Strategies 16, 95–102 (2019).
Leung, Ok., Chakraborty, Ok., Saminathan, A. & Krishnan, Y. A DNA nanomachine chemically resolves lysosomes in stay cells. Nat. Nanotechnol. 14, 176–183 (2019).
Dan, Ok., Veetil, A. T., Chakraborty, Ok. & Krishnan, Y. DNA nanodevices map enzymatic exercise in organelles. Nat. Nanotechnol. 14, 252–259 (2019).
Veetil, A. T. et al. DNA-based fluorescent probes of NOS2 exercise in stay brains. Proc. Natl Acad. Sci. USA 117, 14694–14702 (2020).
Becker, L. et al. Distinctive proteomic signatures distinguish macrophages and dendritic cells. PLoS One 7, e33297 (2012).
Odegaard, J. I. & Chawla, A. Different macrophage activation and metabolism. Annu. Rev. Pathol. 6, 275–297 (2011).
Rodríguez-Prados, J.-C. et al. Substrate destiny in activated macrophages: a comparability between innate, traditional, and various activation. J. Immunol. 185, 605–614 (2010).
Geissmann, F., Gordon, S., Hume, D. A., Mowat, A. M. & Randolph, G. J. Unravelling mononuclear phagocyte heterogeneity. Nat. Rev. Immunol. 10, 453–460 (2010).
Xiong, H. et al. Anti-PD-L1 remedy ends in practical reworking of the macrophage compartment. Most cancers Res. 79, 1493–1506 (2019).
Lawrence, T. & Natoli, G. Transcriptional regulation of macrophage polarization: enabling range with id. Nat. Rev. Immunol. 11, 750–761 (2011).
Martinez, F. O. & Gordon, S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 6, 13 (2014).
Schroder, Ok. et al. Conservation and divergence in Toll-like receptor 4-regulated gene expression in main human versus mouse macrophages. Proc. Natl Acad. Sci. USA 109, E944–E953 (2012).
Thomas, A. C. & Mattila, J. T. “Of mice and males”: arginine metabolism in macrophages. Entrance. Immunol. 5, 479 (2014).
Settembre, C. et al. TFEB hyperlinks autophagy to lysosomal biogenesis. Science 332, 1429–1433 (2011).
Sardiello, M. et al. A gene community regulating lysosomal biogenesis and performance. Science 325, 473–477 (2009).
Napolitano, G. & Ballabio, A. TFEB at a look. J. Cell Sci. 129, 2475–2481 (2016).
Delamarre, L., Pack, M., Chang, H., Mellman, I. & Trombetta, E. S. Differential lysosomal proteolysis in antigen-presenting cells determines antigen destiny. Science 307, 1630–1634 (2005).
Trombetta, E. S. & Mellman, I. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol. 23, 975–1028 (2005).
Lund, A. W. et al. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep. 1, 191–199 (2012).
Satpathy, A. T. et al. Zbtb46 expression distinguishes classical dendritic cells and their dedicated progenitors from different immune lineages. J. Exp. Med. 209, 1135–1152 (2012).
Diment, S. Completely different roles for thiol and aspartyl proteases in antigen presentation of ovalbumin. J. Immunol. 145, 417–422 (1990).
Rodriguez, G. M. & Diment, S. Damaging proteolysis by cysteine proteases in antigen presentation of ovalbumin. Eur. J. Immunol. 25, 1823–1827 (1995).
Matsumoto, Ok. et al. Structural foundation of inhibition of cysteine proteases by E-64 and its derivatives. Biopolymers 51, 99–107 (1999).
Powers, J. C., Asgian, J. L., Ekici, Ö. D. & James, Ok. E. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev. 102, 4639–4750 (2002).
Chakraborty, Ok. et al. Tissue particular concentrating on of DNA nanodevices in a multicellular dwelling organism. Elife 10, e67830 (2021).
Burdette, D. L. & Vance, R. E. STING and the innate immune response to nucleic acids within the cytosol. Nat. Immunol. 14, 19–26 (2013).
Canton, J., Neculai, D. & Grinstein, S. Scavenger receptors in homeostasis and immunity. Nat. Rev. Immunol. 13, 621–634 (2013).
Olson, O. C. & Joyce, J. A. Cysteine cathepsin proteases: regulators of most cancers development and therapeutic response. Nat. Rev. Most cancers 15, 712–729 (2015).
Gocheva, V. et al. IL-4 induces cathepsin protease exercise in tumor-associated macrophages to advertise most cancers development and invasion. Genes Dev. 24, 241–255 (2010).
Gopinathan, A. et al. Cathepsin B promotes the development of pancreatic ductal adenocarcinoma in mice. Intestine 61, 877–884 (2012).
Kerbel, R. S. & Kamen, B. A. The anti-angiogenic foundation of metronomic chemotherapy. Nat. Rev. Most cancers 4, 423–436 (2004).
Sistigu, A. et al. Immunomodulatory results of cyclophosphamide and implementations for vaccine design. Semin. Immunopathol. 33, 369–383 (2011).
Murray, P. J. Macrophage polarization. Annu. Rev. Physiol. 79, 541–566 (2017).
Pastor, F., Kolonias, D., McNamara, J. O. & Gilboa, E. Focusing on 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. Mol. Ther. 19, 1878–1886 (2011).
Siegers, G. M. et al. Anti-leukemia exercise of in vitro-expanded human gamma delta T cells in a xenogeneic Ph+ leukemia mannequin. PLoS ONE 6, e16700 (2011).
Cho, Y., Lee, J. B. & Hong, J. Managed launch of an anti-cancer drug from DNA structured nano-films. Sci. Rep. 4, 4078 (2014).
Lee, H. et al. Molecularly self-assembled nucleic acid nanoparticles for focused in vivo siRNA supply. Nat. Nanotechnol. 7, 389–393 (2012).
Li, S. et al. A DNA nanorobot capabilities as a most cancers therapeutic in response to a molecular set off in vivo. Nat. Biotechnol. 36, 258–264 (2018).
Li, Z., He, X., Luo, X., Wang, L. & Ma, N. DNA-programmed quantum dot polymerization for ultrasensitive molecular imaging of most cancers cells. Anal. Chem. 88, 9355–9358 (2016).
Zhang, P. et al. Close to infrared-guided good nanocarriers for microRNA-controlled launch of doxorubicin/siRNA with intracellular ATP as gasoline. ACS Nano 10, 3637–3647 (2016).
Gustafson, H. H., Holt-Casper, D., Grainger, D. W. & Ghandehari, H. Nanoparticle uptake: the phagocyte drawback. Nano At present 10, 487–510 (2015).
Kelly, C., Jefferies, C. & Cryan, S.-A. Focused liposomal drug supply to monocytes and macrophages. J. Drug Deliv. 2011, 727241 (2011).
Kratz, M. et al. Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. Cell Metab. 20, 614–625 (2014).
Cassetta, L. et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Most cancers Cell 35, 588–602 (2019).
Reardon, C. A. et al. Weight problems and insulin resistance promote atherosclerosis by means of an IFNγ-regulated macrophage protein community. Cell Rep. 23, 3021–3030 (2018).
Eng, J. Ok. et al. A deeper look into Comet—implementation and options. J. Am. Soc. Mass. Spectrom. 26, 1865–1874 (2015).
Becker, L. et al. A macrophage sterol-responsive community linked to atherogenesis. Cell Metab. 11, 125–135 (2010).
Heinecke, N. L., Pratt, B. S., Vaisar, T. & Becker, L. PepC: proteomics software program for figuring out differentially expressed proteins primarily based on spectral counting. Bioinformatics 26, 1574–1575 (2010).
[ad_2]
